Aniling at the DxPx conference in Munich
Aniling is attending the DxPx conference in Munich! Our experience at this event, including one-to-one meetings, has provided us with a great opportunity to connect with industry leaders and investors …
Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.
The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.
Aniling is attending the DxPx conference in Munich! Our experience at this event, including one-to-one meetings, has provided us with a great opportunity to connect with industry leaders and investors …
Aniling is hiring a bioinformatician to join our team! To apply, send the following documents to info@aniling.com and please indicate the reference code Aniling2023/002 in the subject of the mail: …